Xyzal shows significant improvements in quality of life for persistent allergic rhinitis sufferers

and for more than 4 weeks, suggesting chronic inflammation caused by persistent allergen exposure.

Commenting on the data, Professor G. Walter Canonica, one of the authors of the XPERTTM trial, and Director of Allergy and Respiratory Disease at Universit degli Studi di Genova, Italy, said: "For the first time, the XPERTTM study has given us a comprehensive investigation into PER a newly-defined disease subtype. The symptoms of PER are chronic and have a huge impact on a patient's quality of life. The XPERTTM study confirms that long-term treatment with Xyzal® is not only effective at treating the symptoms of persistent allergic rhinitis, but can also significantly improve a patient's quality of life. The study also suggests that continuous treatment for PER is required. This is of particular relevance to people who are suffering chronic symptoms at the height of the hayfever season, and to people whose symptoms will continue well into the autumn due to persistent house dust mite allergy."

The XPERTTM trial also showed that fewer patients treated with Xyzal® suffered from a co-morbid disease, such as asthma and upper respiratory tract infections, compared to patients treated with placebo (54% vs. 71% respectively). There were fewer incidences of asthma (7% vs. 13%) and upper respiratory tract infections (42% vs. 52%) in patients treated with Xyzal® than in patients who received placebo. This reduced co-morbidity resulted in the reduced use of medical resources over the duration of the study, and hence economic savings.1

Further pharmacoeconomic evaluation revealed that treatment of PER with Xyzal® led to fewer working days being lost as a result of uncontrolled symptoms, and to a reduction in loss of productivity at work. Loss of productivity at work and in performing usual daily activities due to allergic rhinitis or comorbidity was halved (-59

Contact: Vicky Blonsky

Page: 1 2 3

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:

(Date:12/4/2019)... ... December 04, 2019 , ... NDA Partners ... , a regulatory toxicology expert with more than 20 years of experience working ... , Dr. Todd has extensive experience with a variety of biologic modalities including ...
(Date:11/27/2019)... , ... November 25, 2019 , ... Though the forecast ... the more than 55 million travelers expected to hit the roads and the skies. ... worth it’s weight in truffle oil will offer a simple design, mouth-watering pictures of ...
(Date:11/27/2019)... ... November 27, 2019 , ... The ... with surface electromyography (sEMG) sensors that measure and display muscle activity in real ... muscles being targeted for treatment. Both patient and therapist can see when exercises ...
Breaking Biology News(10 mins):
(Date:11/9/2019)... BOSTON (PRWEB) , ... November ... ... provider of artificial intelligence (AI)-powered technology for use in pathology research, today ... in liver biopsy samples from patients enrolled in the phase 3 selonsertib ...
(Date:11/6/2019)... FRANCISCO (PRWEB) , ... November 06, 2019 , ... ... biopharma leaders through off-the-record collaboration and dialogue, today announces its East/West CEO ... Hotel in San Francisco. , Kicking off the week of ...
(Date:11/5/2019)... ... November 05, 2019 , ... Focal Healthcare ... Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. By combining information ... Bx 2.0 will give urologists across Europe the ability to perform targeted transrectal ...
(Date:11/2/2019)... ... , ... A clinical trial usually involves many different parties, ... investigators, supply chain managers, manufacturers, IRT, CRAs and so on. Lack of communication ... potentially leading to patient risk. , By having a single source of truth, ...
Breaking Biology Technology:
Cached News: